Addressing the risks of antidepressants among people with alcohol use disorders
- PMID: 38499304
- PMCID: PMC10948179
- DOI: 10.1503/cmaj.150095-l
Addressing the risks of antidepressants among people with alcohol use disorders
Erratum in
-
Correction to "Addressing the risks of antidepressants among people with alcohol use disorders".CMAJ. 2024 Jul 14;196(25):E884. doi: 10.1503/cmaj.240910. CMAJ. 2024. PMID: 39009371 Free PMC article. No abstract available.
Conflict of interest statement
Competing interests:: Evan Wood is a physician who works for Vancouver Coastal Health in the area of withdrawal management and undertakes work in the area of occupational addiction medicine. Dr. Wood is also a professor of medicine based at the University of British Columbia (UBC), a position supported by a Canadian Institutes of Health Research (CIHR) Tier 1 Canada Research Chair and has received salary support from an R01 from the US National Institute on Drug Abuse, paid to UBC. Dr. Wood’s research lab is further supported by CIHR grants to the Canadian Research Initiative in Substance Misuse. Dr. Wood has also undertaken consulting work in legal matters related to substance use disorders and for a mental health company called Numinus Wellness, where Dr. Wood is former chief medical officer; Dr. Wood has also received compensation in the form of equity in Numinus. Dr. Wood reports receiving honoraria for non-industry related lectures and presentations (e.g., at academic or educational conferences), including a talk at the Canadian Society of Addiction Medicine (CSAM) paid by CSAM conference; a Rounds Presentation at Dalhousie University (paid by the University); and an educational talk for the allied health educational platform, Executive Links (all outside the submitted work). Dr. Wood has also received payment for expert reports and expert testimony in legal matters pertaining to substance use disorder, including from the Canadian Medical Protective Association and from trade unions representing workers with possible substance use disorder. Dr. Wood has received travel support from the CIHR. No other competing interests were declared.
Comment on
-
Concerns regarding the recommendation against prescribing selective serotonin reuptake inhibitors in the Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.CMAJ. 2024 Mar 17;196(10):E346-E347. doi: 10.1503/cmaj.149917-l. CMAJ. 2024. PMID: 38499302 Free PMC article. No abstract available.
-
Navigating the nuances of the Canadian guideline's stance on selective serotonin reuptake inhibitors in concurrent alcohol use disorder and mood or anxiety disorders.CMAJ. 2024 Mar 17;196(10):E348. doi: 10.1503/cmaj.150034-l. CMAJ. 2024. PMID: 38499309 Free PMC article. No abstract available.
References
-
- Stokes PRA, Jokinen T, Amawi S, et al. Pharmacological treatment of mood disorders and comorbid addictions: a systematic review and meta-analysis: traitement pharmacologique des troubles de l’humeur et des dépendances comorbides: une revue systématique et une méta-analyse. Can J Psychiatry 2020;65:749–69. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical